VIDAC PHARMA TO PRESENT A POSTER AT THE SITC 2018 MEETING

Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC. The poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach for Simultaneous Targeting of the Tumor and Its Immunosuppressive Microenvironment”, will be presented as part of the “Cellular Metabolism and Antitumor Immunity” session, on Friday, 09 November 2018 from 12:45 – 2:15 p.m. and from 6:30 – 8:00 p.m. Location: Walter E. Washington Convention Center, Exhibit Hall E, Abstract Poster Number: P197.

About Vidac Pharma

Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.

For more information please visit www.vidacpharma.com.

Contact: Shelly Majar +972-2-5952090

###